Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.65 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.65 |
| ▸ | XDH | P47989 | 5/20 | 0.65 |
| ▸ | BCHE | P06276 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 3/20 | 0.65 |
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089208 | 0.83 | PRKDC (0.54) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| Izalpinin SCHEMBL7551775 | 0.82 | MAOA (0.83) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| Izalpinin SCHEMBL29974286 | 0.82 | MAOA (0.83) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL5457154 | 0.81 | MAOA (0.65) | MAOAACHEMAOBPOLBMGAM | |
| SCHEMBL5059689 | 0.81 | MAPT (0.67) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL7088739 | 0.80 | PRKDC (0.47) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| Galangin SCHEMBL29393121 | 0.80 | MEN1 (1.00) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| Galangin SCHEMBL117225 | 0.80 | MEN1 (1.00) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL28106758 | 0.78 | MEN1 (0.67) | ABCB1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL119434 | 0.76 | MEN1 (0.64) | ABCB1MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ABCB1 1078/4885MEN1 2946/4885KMT2A 1686/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ABCB1 1078/4885MEN1 2946/4885KMT2A 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.